Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025

Description

Methicillin-resistant Staphylococcus aureus (MRSA) drugs encompass a group of medications designed to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other commonly used antibiotics. These drugs are specifically selected to target and eliminate MRSA bacteria or hinder their growth. MRSA is a strain of staph bacteria that poses a challenge for treatment due to its resistance to antibiotics.

The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs include lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics containing both lipid and peptide components, and they act by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis. These drugs find applications in treating various indications such as skin infections, bone and joint infections, bacteremia, and infections in animals. Methicillin-resistant Staphylococcus aureus (MRSA) is categorized into hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA) types. The administration of these drugs can be through oral or parenteral routes and is utilized by various end users, including hospitals, clinics, research and academic institutes, among others.

The methicillin-resistant staphylococcus aureus drugs market research report is one of a series of new reports from The Business Research Company that provides methicillin-resistant staphylococcus aureus drugs market statistics, including methicillin-resistant staphylococcus aureus drugs industry global market size, regional shares, competitors with a methicillin-resistant staphylococcus aureus drugs market share, detailed methicillin-resistant staphylococcus aureus drugs market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus drugs industry. This methicillin-resistant staphylococcus aureus drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size has grown steadily in recent years. It will grow from$2.35 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in MRSA cases, high mortality rates

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in MRSA diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired MRSA cases. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance.

The rise in Hospital Acquired Infections (HAIs) is expected to drive the growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market in the future. HAIs are infections that patients develop while receiving treatment in healthcare facilities, occurring 48 hours or more after admission. These infections are attributed to various factors, including contaminated medical equipment, poor hand hygiene among healthcare staff, overuse of antibiotics, prolonged hospital stays, and patients' weakened immune systems. MRSA drugs are crucial for treating these infections by targeting and eliminating MRSA strains that are resistant to standard antibiotics, thereby reducing the spread and severity of infections in healthcare settings. For example, in 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. Thus, the increasing prevalence of MRSA infections is fueling the growth of the MRSA drug market.

The aging population is expected to contribute to the expansion of the MRSA drugs market. Defined as individuals aged 65 and older, the elderly population is more susceptible to infections, including MRSA, due to compromised immune systems associated with aging. As people age, their immune systems become less effective at defending the body against infections, making bacterial infections such as MRSA more prevalent. According to the World Health Organization's October 2022 report, it is projected that by 2030, one in six people globally will be aged 60 or older. The proportion of the population aged 60 and over will increase from 1 billion in 2020 to 1.4 billion, reaching 2.1 billion by 2050. Consequently, the rise in MRSA infections among the elderly is contributing to the growth of the MRSA drugs market.

Product innovation is a key trend gaining traction in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market. Major companies in this sector are focused on developing new products to enhance their market position and improve their competitive edge. For example, in March 2023, Endo, a US-based biopharmaceutical firm, introduced the first generic version of Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules, providing a more affordable treatment option for patients with Helicobacter pylori infections. This launch aims to increase access to effective therapies for gastric ulcers while contributing to cost savings in healthcare, ensuring that more patients can receive the necessary treatment to effectively manage their conditions.

Major companies in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focusing on once-daily dosing regimens to improve patient adherence to treatment, simplify medication schedules, and enhance the overall effectiveness of therapies designed to combat MRSA infections. Once-daily dosing regimens involve taking or administering a drug just once per day. For instance, in August 2024, Sun Pharma, an India-based biotechnology company, launched Tedizolid Phosphate tablets (200 mg), which provide a convenient once-daily dosing option for patients with acute bacterial skin and skin structure infections, including those caused by MRSA. This approach supports better treatment adherence and improved patient outcomes.

In June 2023, Brii Biosciences, a China-based company, acquired the exclusive global rights for BRII-693 from Qpex Biopharma for an undisclosed amount. This acquisition aims to enhance Brii's portfolio of innovative therapeutics targeting infectious diseases, especially those caused by multidrug-resistant pathogens. It strengthens the company's position in the global biopharmaceutical market and expands its ability to address critical unmet medical needs. Qpex Biopharma, a US-based company, specializes in manufacturing drugs for Methicillin-resistant Staphylococcus aureus (MRSA).

Major companies operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market include Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on methicillin-resistant staphylococcus aureus (mrsa) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for methicillin-resistant staphylococcus aureus (mrsa) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The methicillin-resistant staphylococcus aureus (mrsa) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Lipopeptides; Oxazolidinones; Cephalosporin; Tetracycline; Folate Antagonist; Lipoglycopeptide; Other Drug Classes
2) By Indication: Skin Infections; Bone and Joint Infections; Bacteremia; Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA); Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration; Parenteral Administration
5) By End User: Hospitals and Clinics; Research and Academic Institutes; Other End-Users
Subsegments:
1) By Lipopeptides: Daptomycin
2) By Oxazolidinones: Linezolid; Tedizolid
3) By Cephalosporin: Ceftaroline
4) By Tetracycline: Minocycline; Doxycycline
5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole
6) By Lipoglycopeptide: Telavancin; Dalbavancin; Oritavancin
7) By Other Drug Classes: Vancomycin; Clindamycin; Quinupristin Or Dalfopristin
Companies Mentioned: Basilea Pharmaceutica Ltd.; Merck & Co Inc.; Pfizer Inc.; Theravance Biopharma Inc.; Allergan plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24317

1. Executive Summary

2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics

3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies

4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Growth Rate Analysis
5.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Total Addressable Market (TAM)

6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation

6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Lipoglycopeptide
Other Drug Classes
6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Skin Infections
Bone and Joint Infections
Bacteremia
Animal Infections
6.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital-Acquired (HA-MRSA)
Community-Acquired (CA-MRSA)
6.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Administration
Parenteral Administration
6.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals and Clinics
Research and Academic Institutes
Other End-Users
6.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipopeptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Daptomycin
6.7. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Linezolid
Tedizolid
6.8. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ceftaroline
6.9. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Minocycline
Doxycycline
6.10. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Folate Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trimethoprim Or Sulfamethoxazole
6.11. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipoglycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Telavancin
Dalbavancin
Oritavancin
6.12. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vancomycin
Clindamycin
Quinupristin Or Dalfopristin

7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Regional And Country Analysis

7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

8.1. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

9.1. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
9.2. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

10.1. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

11.1. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
11.2. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

12.1. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

13.1. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

14.1. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
14.2. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

15.1. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
15.2. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

16.1. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

17.1. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

18.1. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

19.1. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

20.1. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

21.1. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
21.2. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

22.1. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

23.1. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
23.2. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

24.1. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
24.2. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

25.1. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
25.2. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

26.1. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
26.2. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

27.1. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

28.1. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
28.2. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

29.1. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
29.2. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape And Company Profiles

30.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape
30.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Profiles
- 30.2.1. Basilea Pharmaceutica Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Theravance Biopharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis

31. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Other Major And Innovative Companies

31.1. Cumberland Pharmaceuticals Inc.
31.2. Debiopharm International S.A.
31.3. AbbVie Inc.
31.4. Innovation Pharmaceuticals Inc.
31.5. Melinta Therapeutics Inc.
31.6. Nabriva Therapeutics plc
31.7. Paratek Pharmaceuticals Inc.
31.8. Teva Pharmaceutical Industries Ltd.
31.9. AmpliPhi Biosciences Corporation
31.10. AstraZeneca plc
31.11. Meiji Seika Kaisha Ltd.
31.12. GlaxoSmithKline plc
31.13. Johnson & Johnson
31.14. Sanofi S.A.
31.15. Novartis

32. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

34. Recent Developments In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

35. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market High Potential Countries, Segments and Strategies

35.1 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer